{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:31:26Z","timestamp":1789011086239,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.thromres.2020.11.026","type":"journal-article","created":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T01:23:18Z","timestamp":1606008198000},"page":"7-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Activated factor VIII-mimicking effect by emicizumab on thrombus formation in type 2N von Willebrand disease under high shear flow conditions"],"prefix":"10.1016","volume":"198","author":[{"given":"Hiroaki","family":"Yaoi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Shida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehisa","family":"Kitazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori","family":"Shima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2020.11.026_bb0005","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1182\/blood-2008-10-165621","article-title":"Vanhoorelbeke, von Willebrand factor to the rescue","volume":"113","author":"De Meyer","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.thromres.2020.11.026_bb0010","doi-asserted-by":"crossref","first-page":"17815","DOI":"10.1016\/S0021-9258(18)55200-5","article-title":"The effect of plasma von Willebrand factor on the binding of human factor VIII to thrombin-activated human platelets","volume":"266","author":"Nesheim","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2020.11.026_bb0015","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1021\/bi00350a035","article-title":"Proteolytic processing of human factor VIII; correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity","volume":"25","author":"Eaton","year":"1986","journal-title":"Biochemistry."},{"key":"10.1016\/j.thromres.2020.11.026_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0268-960X(03)00025-0","article-title":"Activation of factor VIII and mechanisms of cofactor action","volume":"18","author":"Fay","year":"2004","journal-title":"Blood Rev."},{"key":"10.1016\/j.thromres.2020.11.026_bb0025","doi-asserted-by":"crossref","first-page":"10451","DOI":"10.1016\/S0021-9258(19)81537-5","article-title":"Association of the factor VIII light chain with von Willebrand factor","volume":"263","author":"Lollar","year":"1988","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2020.11.026_bb0030","doi-asserted-by":"crossref","unstructured":"J.E. Sadler, U. Budde, J.C.J Eikenboom, E.J. Favaloro, F.G. Hill, L. Holmberg, J. Ingerslev, C.A. Lee, D. Lillicrap, P.M. Mannucci, C. Mazurier, D. Meyer, W.L. Nichols, M. Nishino, I.R. Peake, F. Rodeghiero, R. Schneppenheim, Z.M. Ruggeri, A. Srivastava, R.R. Montgomery, A.B. Federici, Working Party on von Willebrand Disease Classification, Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand factor, J. Thromb. Haemost. 4 (2006) 2103\u20132114.","DOI":"10.1111\/j.1538-7836.2006.02146.x"},{"key":"10.1016\/j.thromres.2020.11.026_bb0035","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1182\/blood.V74.5.1591.1591","article-title":"New variant of von Willebrand disease with defective binding to factor VIII","volume":"74","author":"Nishino","year":"1989","journal-title":"Blood."},{"key":"10.1016\/j.thromres.2020.11.026_bb0040","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1111\/hae.12733","article-title":"Clinical phenotype in genetically confirmed von Willebrand disease type 2N patients reflects a haemophilia A phenotype","volume":"21","author":"van Meegeren","year":"2015","journal-title":"Haemophilia."},{"key":"10.1016\/j.thromres.2020.11.026_bb0045","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/1076029606299000","article-title":"Identifying carriers of type 2N von Willebrand disease: procedures and significance","volume":"13","author":"Casonato","year":"2007","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2020.11.026_bb0050","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1055\/s-0031-1281031","article-title":"The international society on thrombosis and haematosis von Willebrand disease database: an update","volume":"37","author":"Hampshire","year":"2011","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2020.11.026_bb0055","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/hae.13366","article-title":"Type 2N von Willebrand disease: characterization and diagnostic difficulties","volume":"24","author":"Casonato","year":"2018","journal-title":"Haemophilia."},{"key":"10.1016\/j.thromres.2020.11.026_bb0060","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/blood-2002-04-1046","article-title":"An Arg760Cys mutation in the consensus sequence of the von Willebrand factor propeptide cleavage site is responsible for a new von Willebrand disease variant","volume":"101","author":"Casonato","year":"2003","journal-title":"Blood."},{"key":"10.1016\/j.thromres.2020.11.026_bb0065","doi-asserted-by":"crossref","unstructured":"P.E. Morange, C. Bickel, V. Nicaud, R. Schnabel, H.J Rupprecht, D. Peetz, K.J. Lackner, F. Cambien, S. Blankenberg, L. Tiret, AtheroGene Investigators, Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study, Arterioscler. Thromb. Vasc. Biol, 26 (2006) 2793\u20132799.","DOI":"10.1161\/01.ATV.0000249406.92992.0d"},{"key":"10.1016\/j.thromres.2020.11.026_bb0070","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1177\/1076029615571630","article-title":"Factoring in factor VIII with acute ischemic stroke","volume":"21","author":"Siegler","year":"2015","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2020.11.026_bb0075","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-02-629873","article-title":"Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease","volume":"126","author":"Gill","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.thromres.2020.11.026_bb0080","doi-asserted-by":"crossref","unstructured":"T. Kitazawa, T. Igawa, Z. Sampei, A. Muto, T. Kojima, T. Soeda, K. Yoshihashi, Y. Okuyama-Nishida, H. Saito, H. Tsunoda, T. Suzuki, H. Adachi, T. Miyazaki, S. Ishii, M. Kamata-Sakurai, T. Iida, A. Harada, K. Esaki, M. Funaki, C. Moriyama, E. Tanaka, Y. Kikuchi, T. Wakabayashi, M. Wada, M. Goto, T. Toyoda, A. Ueyama, S. Suzuki, K. Haraya, T. Tachibana, Y. Kawabe, M. Shima, A. Yoshioka, K. Hattori, A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model, Nat. Med. 18 (2012) 1570\u20131574.","DOI":"10.1038\/nm.2942"},{"key":"10.1016\/j.thromres.2020.11.026_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057479","article-title":"Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity","volume":"8","author":"Sampei","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.thromres.2020.11.026_bb0090","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2020.11.026_bb0095","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia a without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2020.11.026_bb0100","doi-asserted-by":"crossref","unstructured":"S.W. Pipe, M. Shima, M. Lehle, A. Shapiro, S. Chebon, K. Fukutake, N.S. Key, A. Portron, C. Schmitt, M. Podolak-Dawidziak, N Selak-Bienz, C. Hermans, A. Campinha-Bacote, A. Kiialainen, K. Peerlinck, G.G. Levy, V. Jim\u00e9nez-Yuste, Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study, Lancet. Haematol. 6 (2019) e295-e305.","DOI":"10.1016\/S2352-3026(19)30054-7"},{"key":"10.1016\/j.thromres.2020.11.026_bb0105","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.thromres.2020.11.026_bb0110","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/hae.13848","article-title":"A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors","volume":"25","author":"Shima","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2020.11.026_bb0115","article-title":"Emicizumab augments thrombus formation in whole blood from patients with hemophilia a under high shear flow conditions","author":"Yaoi","year":"2020","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.11.026_bb0120","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S1079-9796(03)00033-0","article-title":"Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients","volume":"30","author":"Baronciani","year":"2003","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.thromres.2020.11.026_bb0125","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1055\/s-0038-1651588","article-title":"A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine","volume":"69","author":"Shima","year":"1993","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.11.026_bb0130","doi-asserted-by":"crossref","first-page":"11601","DOI":"10.1016\/S0021-9258(19)78167-8","article-title":"A role for the C2 domain of factor VIII in binding to von Willebrand factor","volume":"269","author":"Saenko","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2020.11.026_bb0135","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1055\/s-0037-1614572","article-title":"Identification of the binding site for an alloantibody to von Willebrand factor which inhibits binding to glycoprotein Ib within the amino-terminal region flanking the A1 domain","volume":"81","author":"Shibata","year":"1999","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.11.026_bb0140","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s12185-014-1720-x","article-title":"Optimization of the automated, CS-2000i\u2122 method for measuring low levels of von Willebrand factor ristocetin cofactor activity (VWF:RCo)","volume":"101","author":"Matsumoto","year":"2015","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.thromres.2020.11.026_bb0145","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1600-0609.1984.tb02764.x","article-title":"Methodology of the one-stage assay of factor VIII (VIII: C)","volume":"41","author":"Over","year":"1984","journal-title":"Scand. J. Haematol. Suppl"},{"key":"10.1016\/j.thromres.2020.11.026_bb0150","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0925-5710(96)00470-7","article-title":"Changes in factor VIII binding capacity of von Willebrand factor and factor VIII coagulant activity in two patients with type 2N von Willebrand disease after hemostatic treatment and during pregnancy","volume":"64","author":"Nishino","year":"1996","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.thromres.2020.11.026_bb0155","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/jth.13118","article-title":"Mild hemophilia a patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity","volume":"13","author":"Yada","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.11.026_bb0160","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1182\/blood-2006-05-021105","article-title":"The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study","volume":"109","author":"James","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.thromres.2020.11.026_bb0165","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/jth.12348","article-title":"The genetics of Canadian type 3 von Willebrand disease: further evidence for codominant inheritance of mutant alleles: a reply to a rebuttal","volume":"11","author":"Bowman","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.11.026_bb0170","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/blood-2013-09-521484","article-title":"Analysis of the role of von Willebrand factor, platelet glycoprotein VI-, and \u03b12\u03b21-mediated collagen binding in thrombus formation","volume":"124","author":"Shida","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.thromres.2020.11.026_bb0175","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1538-7836.2006.01847.x","article-title":"A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD)","volume":"4","author":"Tosetto","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.11.026_bb0180","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII\u2013mimetic function of humanized bispecific antibody in hemophilia a","volume":"374","author":"Shima","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2020.11.026_bb0185","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/bloodadvances.2017006684","article-title":"Long-term safety and efficacy of emicizumab in a phase 1\/2 study in patients with hemophilia a with or without inhibitors","volume":"1","author":"Shima","year":"2017","journal-title":"Blood. Adv."},{"key":"10.1016\/j.thromres.2020.11.026_bb0190","doi-asserted-by":"crossref","first-page":"27424","DOI":"10.1074\/jbc.271.44.27424","article-title":"Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition","volume":"271","author":"Saenko","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2020.11.026_bb0195","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/hae.12610","article-title":"Comprehensive evaluation of haemostatic function in von Willebrand disease patients using a microchip-based flow chamber system","volume":"21","author":"Ogiwara","year":"2015","journal-title":"Haemophilia."},{"key":"10.1016\/j.thromres.2020.11.026_bb0200","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/jth.13749","article-title":"Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice","volume":"15","author":"Swystun","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.11.026_bb0205","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2141.1994.tb05079.x","article-title":"Factor VIII, ABO blood group and the incidence of ischaemic heart disease","volume":"88","author":"Meade","year":"1994","journal-title":"Brit. J. Haematol."},{"key":"10.1016\/j.thromres.2020.11.026_bb0210","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1161\/01.ATV.12.9.1063","article-title":"The PLAT study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. PLAT study group. Progetto Lombardo Atero-Trombosi (PLAT) study group","volume":"12","author":"Cortellaro","year":"1992","journal-title":"Arterioscler. Thromb."},{"key":"10.1016\/j.thromres.2020.11.026_bb0215","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.thromres.2014.03.028","article-title":"Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII","volume":"134","author":"Zollner","year":"2014","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2020.11.026_bb0220","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/jth.14135","article-title":"Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies","volume":"16","author":"Nogami","year":"2018","journal-title":"J. Thromb. Haemost."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384820306344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384820306344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:42:45Z","timestamp":1758735765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384820306344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":44,"alternative-id":["S0049384820306344"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2020.11.026","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activated factor VIII-mimicking effect by emicizumab on thrombus formation in type 2N von Willebrand disease under high shear flow conditions","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2020.11.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}